Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 19/20 | 0.83 |
| ▸ | JAK1 | P23458 | 18/20 | 0.83 |
| ▸ | JAK3 | P52333 | 17/20 | 0.83 |
| ▸ | TYK2 | P29597 | 6/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12888268 | 0.91 | JAK2 (1.00) | JAK2JAK1JAK3TYK2 | |
| SCHEMBL12888272 | 0.91 | JAK2 (1.00) | JAK2JAK1JAK3TYK2 | |
| SCHEMBL12888273 | 0.91 | JAK2 (1.00) | JAK2JAK1JAK3TYK2 | |
| SCHEMBL16199900 | 0.91 | JAK2 (1.00) | JAK2JAK1JAK3TYK2 | |
| SCHEMBL12888276 | 0.88 | JAK1 (0.84) | JAK2JAK1JAK3TYK2 | |
| Peficitinib SCHEMBL16199902 | 0.84 | JAK3 (1.00) | JAK2JAK1JAK3TYK2 | |
| Peficitinib SCHEMBL16199899 | 0.84 | JAK3 (1.00) | JAK2JAK1JAK3TYK2 | |
| Peficitinib SCHEMBL22404910 | 0.84 | JAK3 (1.00) | JAK2JAK1JAK3TYK2 | |
| Peficitinib SCHEMBL9990240 | 0.84 | JAK3 (1.00) | JAK2JAK1JAK3TYK2 | |
| Peficitinib SCHEMBL24212690 | 0.84 | JAK3 (1.00) | JAK2JAK1JAK3TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220125933-A1 | LIPID PRODRUGS OF JAK INHIBITORS AND USES THEREOF | SEAPORT THERAPEUTICS, INC. | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220125933-A1 | LIPID PRODRUGS OF JAK INHIBITORS AND USES THEREOF | JAK1, JAK2, JAK3 | JAK2 2/4885JAK1 1/4885JAK3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.